Crypto News

Aug 24, 2026

SELLAS Life Sciences (SLS) Stock Rockets 255% on Phase 3 Leukemia Trial Progress

Stocks

SELLAS Life Sciences (SLS) stock soars 255% YTD as Phase 3 AML trial hits critical milestone. Analysts set $10 target amid rising institutional interest.

The post SELLAS Life Sciences (SLS) Stock Rockets 255% on Phase 3 Leukemia Trial Progress appeared first on Blockonomi.

Source: Blockonomi →

Related News

Trending Category

$BMNR200-day moving average24/7 trading4-Year Cycle50-Week Moving AverageAB 2409AGIXAIAI AgentsAI Data CentersAI IPO marketAI InfrastructureAI StocksAI automationAI backlashAI capital rotationAI spendingAMD StockAMLAML compliance

Latest News